High PD-L1 expression in the tumor microenvironment (TME) has been correlated with response to PD-1/PD-L1 blockade therapy and is used as a biomarker for the initiation of immunotherapy in NSCLC (1, 4, 9). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.